MAY 21·MSNMed
Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates
Bolt Biotherapeutics, Inc. (BOLT) reported a wider-than-anticipated loss and revenue that fell short of analyst estimates for the first quarter. The company announced a loss of $0.62 per share, exceeding the average analyst estimate of a $0.57 loss, and posted revenues of $2.20 million, significantly lower than the $5.53 million expected.